This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Claudio, P. P. Articles by Giordano, A. Search for Related Content PubMed PubMed Citation Articles by Claudio, P. P. Articles by Giordano, A.

The RB2/p130 Gene: The Latest Weapon in the War against Lung Cancer?¹

Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, and Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, Pennsylvania 19107 [P. P. C., A. G.]; Universita’ degli Studi di Napoli "Federico II," Dipartimento di Scienze Odontostomatologiche e Maxillo Facciali, Napoli 80131, Italy [P. P. C.]; and Istituto di Malattie dell’Apparato Respiratorio, II Universita’ degli Studi di Napoli, Istituto di Ricerca Cardio-Pneumologica A. O. "Monaldi," Napoli, Italy 80131 [M. C.]

Lung cancer is the second cause of death after cardiovascular diseases and is the major cause of cancer deaths in the Western world. Large scale screening trials conducted 15–20 years ago using chest X-rays and sputum cytology were able to detect stage I cancers but failed to impact on survival. This is because of the early metastatic potential of small primary tumors. It is important then to detect lung cancer at an earlier stage, studying and identifying genetic lesions that could indicate a new target(s) for gene therapy. The retinoblastoma-related gene pRb2/p130, a new tumor suppressor gene cloned in 1993, is emerging as one of the candidate markers and targets for gene therapeutic approach. Effective genetic therapy requires both a genetic material to be used therapeutically and a means to deliver it. A scope for this review is to examine some of the gene delivery systems mostly used, discussing their weaknesses and strengths, and to discuss the role of pRb2/p130 in lung cancer.

This article has been cited by other articles:

				M. Caputi, A. M. Groeger, V. Esposito, A. De Luca, V. Masciullo, A. Mancini, F. Baldi, E. Wolner, and A. Giordano Loss of pRb2/p130 Expression Is Associated with Unfavorable Clinical Outcome in Lung Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3850 - 3856. [Abstract] [Full Text] [PDF]

				L Leoncini, S Lazzi, C Bellan, and P Tosi Cell kinetics and cell cycle regulation in lymphomas J. Clin. Pathol., September 1, 2002; 55(9): 648 - 655. [Abstract] [Full Text] [PDF]

				X. Tong, D. Xie, J. O'Kelly, C. W. Miller, C. Muller-Tidow, and H. P. Koeffler Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer J. Biol. Chem., December 7, 2001; 276(50): 47709 - 47714. [Abstract] [Full Text] [PDF]